Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Build A Bear Workshop Inc (BBW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Build A Bear Workshop Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Build A Bear Workshop Inc trades at $34 (market cap $431.54M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 92.4× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.67% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BBW | |
|---|---|---|
Market Cap | $39.89B | $431.54M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $75.85 |
52-Week Low | $278.09 | $29.84 |
Enterprise Value | $38.15B | $530.98M |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Build-A-Bear Workshop (BBW) trades at $34.42, up 10.5% today, showing strong momentum despite a bearish technical outlook. The company demonstrates solid fundamentals with a P/E of 8.06 and robust profitability metrics including 35.87% ROE. Recent Q1 2026 earnings beat expectations with $1.03 EPS versus $0.76 estimate, though revenue guidance was revised downward. The company completed a planned CEO transition in June 2026 and maintains a debt-free balance sheet with consistent dividend payments.
BBW presents a compelling value opportunity with attractive valuation multiples and strong analyst support (72.7% buy ratings, $62.50 consensus target). However, near-term headwinds include consumer spending pressures and international expansion execution risks. The stock's 40% YTD decline creates potential for recovery if the company can successfully implement its four-pillar growth strategy in the second half of 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →
